心血管治療薬市場：薬剤タイプ、適応疾患、投与経路、購入形態、エンドユーザー別-2025-2030年の世界予測

心血管治療薬市場は、2023年に826億5,000万米ドルと評価され、2024年には901億3,000万米ドルに達すると予測され、CAGR 9.15％で成長し、2030年には1,526億1,000万米ドルに達すると予測されています。

心血管治療薬市場には、高血圧、心不全、不整脈、冠動脈疾患など、さまざまな心臓関連疾患の治療に使用される医薬品が幅広く含まれています。これらの医薬品は、世界の死亡原因の上位を占める心血管疾患の管理に不可欠です。心血管治療薬の必要性は、患者の転帰を大幅に改善し、入院を減らし、生活の質を高める能力にあります。その用途は、急性期、慢性期、予防医療など多岐にわたる。最終使用範囲には、病院、診療所、外来サービス、処方箋による個人使用などが含まれます。

この市場の主な成長促進要因には、心血管疾患の有病率の増加、高齢者人口の増加、薬剤開発と個別化医療における継続的な進歩が含まれます。さらに、効果的な治療オプションに対する需要の急増が市場拡大の原動力となっています。精密医療に焦点を当てた創薬と開発における人工知能の統合は、新たな成長の道を提供します。しかし、厳しい規制の枠組み、医薬品開発に関連する高コスト、潜在的な副作用などの課題が残っており、これが市場成長の妨げになる可能性があります。

潜在的なビジネスチャンスを活用するために、利害関係者は生分解性ステントや薬剤溶出性バルーンなどの革新的な薬剤製剤に注目すべきです。製薬企業とバイオテクノロジー企業の提携は、画期的な治療法の研究開発を促進します。さらに、患者の遠隔モニタリングとアドヒアランスのためのデジタルヘルス技術に投資することで、薬剤の有効性と患者の関与を高めることができます。大規模な臨床試験の必要性や医薬品回収のリスクといった限界は、依然として大きな障壁となっています。

事業成長のためには、遺伝子治療、RNAベースの薬剤、ドラッグデリバリーにおけるナノテクノロジーの応用の研究を優先させることが、変革をもたらす可能性があります。全体として、心血管治療薬市場は革新の態勢を整えているが、その潜在能力を効果的にフル活用するためには、複雑な規制を乗り越え、経済的制約に対処する必要があります。

市場力学：急速に進化する心血管治療薬市場の主要市場インサイトを公開

心血管治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 心血管疾患の有病率の上昇
  • 医薬品開発のための研究開発投資の増加
  • 心血管疾患の予防と制御に対する政府の取り組み
• 市場抑制要因
  • 製品回収と心血管治療薬の高コスト
• 市場機会
  • 心血管治療薬に対する有利な償還政策とプログラム
  • 心血管疾患治療用新薬のイントロダクション
• 市場の課題
  • 効率的で安全な医薬品開発の複雑さ

ポーターの5つの力：心血管治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：心血管治療薬市場における外部からの影響の把握

外部マクロ環境要因は、心血管治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析心血管治療薬市場における競合情勢の把握

心血管治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス心血管治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、心血管治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 心血管疾患の罹患率の上昇
    • 医薬品開発のための研究開発投資の増加
    • 心血管疾患の予防と管理に関する政府の取り組み
  • 抑制要因
    • 製品リコールと心血管治療薬の高コスト
  • 機会
    • 心血管治療薬の有利な償還ポリシーとプログラム
    • 心血管疾患治療のための新薬のイントロダクション
  • 課題
    • 効率的かつ安全な医薬品開発の複雑さ
• 市場セグメンテーション分析
  • 薬剤の種類：特定の種類の腎臓疾患の治療にアンジオテンシン阻害剤の需要が増加
  • 疾患適応症：高血圧の管理における心血管疾患の使用の増加
  • 購入方法：心臓の健康に関連する軽度の症状を管理するための市販薬心血管治療薬の使用が増加
  • エンドユーザー：急性疾患の治療に病院薬局で心血管治療薬の採用が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 心血管治療薬市場薬の種類別

• アンジオテンシン阻害剤
• 抗凝固薬
• 抗高脂血症
• 降圧剤
• 抗血小板薬

第7章 心血管治療薬市場：疾患適応症別

• 不整脈
• 冠動脈疾患
• 高脂血症
• 高血圧

第8章 心血管治療薬市場：投与経路別

• 静脈内
• オーラル
• 皮下

第9章 心血管治療薬市場購入方法別

• 市販薬
• 処方薬

第10章 心血管治療薬市場：エンドユーザー別

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 南北アメリカの心血管治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の心血管治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの心血管治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ブリストル・マイヤーズ、心血管疾患のRNA医薬品に1億米ドルを投資
  • 米国FDA、レキシコン・ファーマの心不全治療薬を承認
  • グレンマーク・ファーマシューティカルズ、インドで心不全治療薬を発売

企業一覧

• Gilead Sciences, Inc.
• Otsuka Holdings Co., Ltd.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• Chiesi USA, Inc.
• Cornerstone Therapeutics Inc.
• Pfizer Inc.
• Daiichi Sankyo Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Eisai Co., Ltd.
• Ferring B.V.
• Sanofi S.A.
• Novo Nordisk A/S
• Boehringer Ingelheim GmbH
• Par Pharmaceutical by Endo International
• CYTOKINETICS, Incorporated
• Bristol-Myers Squibb Company
• Bausch Health Companies Inc.
• Abbott Laboratories
• Auro Pharma Inc.
• WellSpring Pharmaceutical Corporation
• Merck KGaA
• AstraZeneca PLC
• Zydus Group
• Baxter International Inc.
• Apotex Inc.
• Bayer AG
• Cipla Limited

LIST OF FIGURES

• FIGURE 1. CARDIOVASCULAR DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. CARDIOVASCULAR DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. CARDIOVASCULAR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. CARDIOVASCULAR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CARDIOVASCULAR DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CARDIOVASCULAR DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANGIOTENSIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERLIPIDEMIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERTENSIVE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERLIPIDAEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 45. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 49. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 72. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 76. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 77. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 81. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 163. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 164. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 165. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 166. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 167. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 183. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 184. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 185. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 187. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 188. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 189. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 190. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 191. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 192. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 238. CARDIOVASCULAR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 239. CARDIOVASCULAR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Cardiovascular Drugs Market was valued at USD 82.65 billion in 2023, expected to reach USD 90.13 billion in 2024, and is projected to grow at a CAGR of 9.15%, to USD 152.61 billion by 2030.

The cardiovascular drugs market encompasses a wide range of medications used to treat various heart-related conditions such as hypertension, heart failure, arrhythmias, and coronary artery diseases. These drugs are critical for managing cardiovascular diseases, which are among the leading causes of mortality globally. The necessity of cardiovascular drugs lies in their ability to significantly improve patient outcomes, reduce hospital admissions, and enhance quality of life. Their applications range across managing acute episodes, chronic conditions, and preventive care. End-use scopes include hospitals, clinics, and outpatient services, as well as individual use under prescription.

Key growth drivers in this market include the increasing prevalence of cardiovascular diseases, a rising elderly population, and ongoing advancements in drug development and personalized medicine. Moreover, the surge in demand for effective therapeutic options drives market expansion. The integration of artificial intelligence in drug discovery and development, focusing on precision medicine, offers new growth avenues. However, challenges persist, such as stringent regulatory frameworks, high costs associated with drug development, and potential side effects, which can hinder market growth.

To tap into potential opportunities, stakeholders should focus on innovative drug formulations, including biodegradable stents and drug-eluting balloons. Collaborations between pharmaceutical companies and biotech firms can facilitate research and development of breakthrough therapies. Additionally, investing in digital health technologies for remote patient monitoring and adherence could enhance drug efficacy and patient engagement. Limitations such as the need for extensive clinical trials and the risk of drug recalls remain significant barriers.

For business growth, prioritizing research in gene therapy, RNA-based drugs, and exploring applications of nanotechnology in drug delivery could prove transformational. Overall, the cardiovascular drugs market is poised for innovation, though it requires navigating complex regulatory waters and addressing economic constraints to harness its full potential effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cardiovascular Drugs Market

The Cardiovascular Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising Prevalence of Cardiovascular Disorders
  • Increasing R&D Investments for Drug Development
  • Government Initiatives for Prevention & Control of Cardiovascular Diseases
• Market Restraints
  • Product Recalls and High Cost of Cardiovascular Drugs
• Market Opportunities
  • Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
  • Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
• Market Challenges
  • Complexities in Efficient and Safe Drug Development

Porter's Five Forces: A Strategic Tool for Navigating the Cardiovascular Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cardiovascular Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cardiovascular Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cardiovascular Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cardiovascular Drugs Market

A detailed market share analysis in the Cardiovascular Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cardiovascular Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cardiovascular Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cardiovascular Drugs Market, highlighting leading vendors and their innovative profiles. These include Gilead Sciences, Inc., Otsuka Holdings Co., Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Chiesi USA, Inc., Cornerstone Therapeutics Inc., Pfizer Inc., Daiichi Sankyo Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., Ferring B.V., Sanofi S.A., Novo Nordisk A/S, Boehringer Ingelheim GmbH, Par Pharmaceutical by Endo International, CYTOKINETICS, Incorporated, Bristol-Myers Squibb Company, Bausch Health Companies Inc., Abbott Laboratories, Auro Pharma Inc., WellSpring Pharmaceutical Corporation, Merck KGaA, AstraZeneca PLC, Zydus Group, Baxter International Inc., Apotex Inc., Bayer AG, and Cipla Limited.

Market Segmentation & Coverage

This research report categorizes the Cardiovascular Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Angiotensin Inhibitors, Anticoagulants, Antihyperlipidemic, Antihypertensive, and Antiplatelet Drugs.
• Based on Disease Indication, market is studied across Arrhythmia, Coronary Artery Disease, Hyperlipidaemia, and Hypertension.
• Based on Route of Administration, market is studied across Intravenous, Oral, and Subcutaneous.
• Based on Mode of Purchase, market is studied across Over-The-Counter Drugs and Prescription-Based Drugs.
• Based on End-Users, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising Prevalence of Cardiovascular Disorders
    • 5.1.1.2. Increasing R&D Investments for Drug Development
    • 5.1.1.3. Government Initiatives for Prevention & Control of Cardiovascular Diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Product Recalls and High Cost of Cardiovascular Drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
    • 5.1.3.2. Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities in Efficient and Safe Drug Development
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Increasing need for angiotensin inhibitors to treat certain types of kidney diseases
  • 5.2.2. Disease Indication: Rising usage of cardiovascular diseases for the management of hypertension
  • 5.2.3. Mode of Purchase: Rising usage of over-the-counter cardiovascular drugs for managing minor symptoms associated with heart health
  • 5.2.4. End-Users: Growing adoption of cardiovascular drugs by hospitals pharmacies for the treatment of acute conditions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cardiovascular Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Angiotensin Inhibitors
• 6.3. Anticoagulants
• 6.4. Antihyperlipidemic
• 6.5. Antihypertensive
• 6.6. Antiplatelet Drugs

7. Cardiovascular Drugs Market, by Disease Indication

• 7.1. Introduction
• 7.2. Arrhythmia
• 7.3. Coronary Artery Disease
• 7.4. Hyperlipidaemia
• 7.5. Hypertension

8. Cardiovascular Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Intravenous
• 8.3. Oral
• 8.4. Subcutaneous

9. Cardiovascular Drugs Market, by Mode of Purchase

• 9.1. Introduction
• 9.2. Over-The-Counter Drugs
• 9.3. Prescription-Based Drugs

10. Cardiovascular Drugs Market, by End-Users

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas Cardiovascular Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Cardiovascular Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Cardiovascular Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Bristol Myers pours USD 100 million into RNA drugs for cardiovascular diseases
  • 14.3.2. U.S. FDA Approves Lexicon Pharma's Drug for Heart Failure
  • 14.3.3. Glenmark Pharmaceuticals Launches Drug to Treat Heart Failure in India

Companies Mentioned

• 1. Gilead Sciences, Inc.
• 2. Otsuka Holdings Co., Ltd.
• 3. Novartis AG
• 4. Teva Pharmaceutical Industries Ltd.
• 5. Johnson & Johnson Services, Inc.
• 6. Chiesi USA, Inc.
• 7. Cornerstone Therapeutics Inc.
• 8. Pfizer Inc.
• 9. Daiichi Sankyo Co., Ltd.
• 10. Eli Lilly and Company
• 11. F. Hoffmann-La Roche Ltd.
• 12. Eisai Co., Ltd.
• 13. Ferring B.V.
• 14. Sanofi S.A.
• 15. Novo Nordisk A/S
• 16. Boehringer Ingelheim GmbH
• 17. Par Pharmaceutical by Endo International
• 18. CYTOKINETICS, Incorporated
• 19. Bristol-Myers Squibb Company
• 20. Bausch Health Companies Inc.
• 21. Abbott Laboratories
• 22. Auro Pharma Inc.
• 23. WellSpring Pharmaceutical Corporation
• 24. Merck KGaA
• 25. AstraZeneca PLC
• 26. Zydus Group
• 27. Baxter International Inc.
• 28. Apotex Inc.
• 29. Bayer AG
• 30. Cipla Limited